RBR-35734p招募中1 期
Randomized clinical trial phase I/II for the use of angiotensin-(1-7) in the treatment of severe infection by Sara-CoV-2
Angitec0 个研究点开始时间: 2020年8月5日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 17Y 至 81Y（—）
入选标准
- •Age: less than 17 and less or equal to 81 years; Admission to the Intensive Care Unit with severe pneumonia criteria (clinical signs of pneumonia + one of the following criteria: respiratory rate greater than 30 irpm; signs of respiratory effort, SatO2 less than 90% in room air); COVID-19 confirmed or highly suspicious (positive contact or suggestive image)
排除标准
- •Patients diagnosed with cancer (at any stage); Hemodynamic instability (need for vasopressors); Pregnant women; Immunocompromised patients; Exclusive Palliative Care; Inclusion in any other interventionist study; Heart failure as a predominant cause of acute respiratory failure; decompensated liver cirrhosis; HIV +; Dialysis; Home / long-term oxygen therapy; Idiopathic pulmonary fibrosis
研究者
相似试验
已完成
1 期
Clinical trial of ozone therapy in mild to moderate Covid-19 subjects.CTRI/2020/07/026354Bisleri Charitable Trust60
进行中（未招募）
1 期
Evaluating the effect of Loratadine associated with Rapamune in Lymphagioleiomyomatosis (LAM).EFFECT OF LORATADINE ON LYMPHANGIOLEIOMYOMATOSISMedDRA version: 21.0Level: PTClassification code 10049459Term: LymphangioleiomyomatosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2020-000702-29-ESIDIBELL (Institut d’Investigació Biomédica de Bellvitge)62
进行中（未招募）
1 期
An open, randomized clinical phase I/II trial to investigate maximum tolerated dose, efficacy, and safety of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide compared to lenalidomide/low-dose dexamethasone combined with single cyclophosphamide doses IV in patients with relapsed/refractory multiple myelomaEUCTR2008-003829-16-DEGMIHO - Gesellschaft für medizinische Innovation Hämatologie und Onkologie mbH70
进行中（未招募）
1 期
An early-stage clinical trial to evaluate the safety and effectiveness of GDC-0032 when given alongside Tamoxifen to patients with HER2 negative advanced breast cancer, who have previously received hormone treatmentHormone receptor positive metastatic breast cancerMedDRA version: 19.0Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 100000004864EUCTR2013-003947-51-GBKI-AV322
已完成
2 期
Phase I/prospective randomized phase II trial Of the Safety and Efficacy of tamoxifen in combination with the Isoform selective Pi3K inhibitor GDC-0032 compared with tamoxifen alONe in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment (POSEIDON trial)10006291breast cancerNL-OMON55501ederlands Kanker Instituut120